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 Anti-infl ammatory 
 Toll-like receptors as therapeutic 
targets in cystic fi brosis 
 Catherine M  Greene † ,  Peter  Branagan &  Noel G  McElvaney 
 Beaumont Hospital, Education and Research Centre, Respiratory Research Division, Royal College of 
Surgeons in Ireland, 9 Dublin, Ireland 
 Background : Toll-like receptors (TLRs) are pattern recognition receptors that 
act as a first-line of defence in the innate immune response by recognising 
and responding to conserved molecular patterns in microbial factors and 
endogenous danger signals. Cystic fibrosis (CF)-affected airways represent a 
milieu potentially rich in TLR agonists and the chronic inflammatory phenotype 
evident in CF airway epithelial cells is probably due in large part to activation 
of TLRs.  Objective/methods : To examine the prospects of developing novel 
therapies for CF by targeting TLRs. We outline the expression and function 
of TLRs and explore the therapeutic potential of naturally-occurring and 
synthetic TLR inhibitors for CF.  Results/conclusion : Modulation of TLRs has 
therapeutic potential for the inflammatory lung manifestations of CF. 
 Keywords:  cystic fibrosis ,  inflammation ,  innate immunity ,  therapeutics ,  toll-like receptors 
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 1.  Introduction 
 The innate immune system plays a key role in regulating responses to infection 
and inflammation in the pathophysiology of cystic fibrosis (CF). Toll-like receptors 
(TLR) are important components of innate immunity that are activated in 
response to both infective and inflammatory stimuli. Here we focus on the current 
paradigm regarding the function of TLRs. The important roles of each member 
of the TLR family in regulating pro-inflammatory gene expression in response to 
microbial and endogenous agonists in the CF lung is addressed. The major signalling 
pathways activated by TLRs are explained and methods to target either TLRs or 
their signalling pathways using microbial and naturally-occurring endogenous 
inhibitors or antiproteases are described. Current treatment regimens and how 
they may affect TLR function in the CF lung are also discussed. 
 2.  Infection and infl ammation in the pathophysiology of CF 
 CF is caused by mutations of the CF transmembrane conductance regulator 
(CFTR) gene. It is a lethal hereditary disorder that is relatively common in 
Europe and North America, accounting for 1 in 3000 live births. Amongst 
Caucasians, 1 in 20 is a heterozygotic carrier of a mutant CFTR allele. Other races 
including Hispanics, Blacks and Asians are also affected but in smaller numbers  [1] . 
The clinical consequences of CF are protean with multiple organs potentially 
being involved. The liver, pancreas and intestinal tract can all be affected, however 
the major causes of morbidity and mortality are the lung disease  [2] . This is 
characterised by chronic airway infections with  Pseudomonas, Staphylococcus, 
Haemophilus, Aspergillus and  Burkholderia species, overproduction of thick mucus 
and inflammation  [2,3] . Other complications of CF affecting the airways can 
include haemoptysis, pneumothorax, pulmonary hypertension and  cor pulmonale 
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Although improvements in healthcare have enhanced survival 
the outlook for individuals with CF could be better. 
 The lung disease in CF is characterised by infection/
colonization, inflammation and mucus overproduction  [4] . 
Inflammation in CF is to a large extent compartmentalised 
to the lung epithelial surface and represents an interaction 
between bacteria, inflammatory cells, their secretions and 
epithelial cells and their receptors. It also represents an inability 
of the lung’s innate defences to clear the infective causes of 
inflammation. Historically the lung has been perceived as an 
organ primarily involved in gas exchange. However, due to 
its unique relationship with the environment, the lung must 
defend itself from infection by numerous inhaled micro-
organisms. Various innate defences protect the lung from 
infection, including the cough reflex, the mucociliary escalator, 
and the intrinsic antimicrobial properties of the mucosal 
surface. In addition, an extensive alveolar-capillary membrane 
containing immune and non-immune cells is exposed to 
microbial challenges. As a result, pulmonary tissues generate 
a brisk innate host response to both inhaled and haematogenous 
pathogens in order to clear the offending microorganism 
and preserve gaseous exchange. Innate immunity plays a key 
role in these events in the CF lung. 
 3.  TLR expression and function 
 The TLR family represent a conserved and increasingly 
well-characterised group of pattern recognition receptors 
(PRRs). TLRs constitute the most significant component of 
pulmonary PRRs and can recognize and discriminate a 
diverse array of microbial antigens. The family comprises a 
selection of transmembrane proteins that constitute an 
important unit of the innate immune system. TLR expression 
is widespread and includes, but is not limited to, cells of 
myeloid and lymphoid origin, endothelial and epithelial cells. 
 First identified in the fruitfly  Drosophila melanogaster , the 
 Drosophila or dToll was initially characterised as a factor 
regulating embryogenic –ventral axis formation. Later dToll 
was shown to act as a key receptor regulating antimicrobial 
defense in the adult fly  [5] . In 1991 Gay and Keith reported 
the identification of structural and functional similarities 
between dToll and the mammalian Type I IL-1 receptor 
(IL-1RI)  [6] an important receptor in innate immunity. This 
prompted a surge of research leading to the identification and 
partial characterisation of ten human TLRs sharing sequence 
similarity with the cytosolic signalling domain of IL-1RI. 
 TLRs are germ-line-encoded pattern recognition receptors. 
Each has a role in the innate immune response  [7] . An 
extracellular leucine-rich repeat (LRR) ligand recognition 
domain and an intracellular signalling domain integrating 
the functional signature motif of TLRs, the so-called TIR 
(Toll/interleukin-1 receptor) domain, characterises all of the 
TLR type I transmembrane proteins. The conserved cytosolic 
TIR domain consists of up to 200 amino acids  [8,9] essential 
for signalling whilst the external LRR motifs probably confer 
specificity to TLRs with respect to their pattern recognition 
properties  [10] . TLR4, the mammalian lipopolysaccharide 
(LPS) receptor, was the first mammalian TLR to be identified. 
Its properties were elucidated from studies on the LPS hypo-
responsive mouse strain C3H/HeJ  [11] which have a domi-
nant-negative Pro712His mutation in the TIR domain of their 
TLR4 and are resistant to challenges with lethal doses of LPS. 
 TLRs facilitate the recognition and discrimination of 
invading microbes and induce an appropriate immune response. 
They are activated by specific microbial agonists including 
ones derived from bacteria, viruses, mycoplasma, yeasts 
and protozoa ( Figure 1 ). TLR4, the principal receptor 
for Gram-negative LPS can also recognise other microbial 
agonists including respiratory syncytial virus (RSV)  [12] , 
 Chlamydia pneumonia , Hsp60, flavolipin and murine retro-
viruses F protein  [13-16] . Interestingly a number of endogenous 
signals can also activate TLR4 and other TLRs including 
hyalurnonan and neutrophil elastase (see below)  [17,18] . 
 TLR2 appears to recognize a broad repertoire of agonists 
and is a functionally important PRR in the airways, which 
can respond to lipoteichoic acid, peptidoglycan and 
 M. pneumoniae  [19-21] . As a dimer with other TLRs, TLR2 
confers responsiveness to a selection of agonists  [22] . For 
example, with TLR1 it recognizes triacylated lipopeptides, 
Gram-positive lipoteichoic acid and  Streptococcus pneumoniae  [23] , 
whereas with TLR6 it recognises diacylated lipopeptides  [24] . 
There has been a single report of TLR2’s involvement in the 
response to flagellin  [25] . 
 TLRs 3, 7, 8 and 9 have roles in the recognition of 
nucleic acids. TLR3 responds to double-stranded (ds)RNA  [26,27] 
a potential by-product in virally infected cells. TLRs 7 and 8, 
although not well expressed by lung epithelium  [28] are 
expressed by immune cells within the lung and have a known 
role in the antiviral response  [29,30] . Their major agonists are 
guanosine- and uridine-rich single-stranded (ss)RNA found in 
many viruses  [31,32] . Microbial DNA featuring unmethylated 
CpG (uCpG) dinucleotides motifs activate TLR9  [33] . These 
occur frequently in bacterial but not mammalian DNA. 
 Flagellin is a protein subunit of bacterial flagellae expressed 
by Gram-negative bacteria. It can induce TLR5-dependent 
signalling  [34] . Airway epithelial cells utilise TLR5 in their 
responses to  Pseudomonas aeruginosa ,  Legionella  pneumophila 
and  Bordetella bronchispetica  [35-38] . TLR10 is an orphan 
member of the human TLR family  [39] . 
 4.  TLR signalling pathways 
 An important feature of TLR signal transduction is that highly 
conserved pathways can be activated by the different TLRs. 
Thus, both TLRs and their intracellular signalling molecules 
represent key inhibitory targets for therapeutic drug design. 
 Activation of TLRs can lead to downstream signalling 
cascades resulting in the activation of pro-inflammatory gene 
transcription. These TLR-mediated changes in gene expression 
are critically dependent on the cytosolic TIR domain  [7,40] . 
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TIRs provide a scaffold for protein-protein interactions most 
notably those leading to the activation of NF- κ B and the 
interferon regulatory factors (IRFs)  [41,42] . Activation of AP1 
and the MAPKs jun N-terminal kinase (JNK), p38 and 
extracellular signal-regulated kinase (ERK)1/2  [43] are other 
classical signals regulated by TLR signalling. 
 Agonist-induced homo- or heterodimerisation of TLRs 
represents the first step in all TLR signalling cascades. 
TLR4 uniquely requires two accessory proteins for full 
responsiveness to its agonists; myeloid differentiation protein-2 
(MD-20, a soluble glycoprotein on the outer surface of 
the cell membrane  [44] and CD14, a glycophospatidyl 
inositol-anchored receptor which binds to LPS–LPS-binding 
protein complexes  [45] . NF- κ B activation by TLRs then 
occurs in response to recruitment of TIR-domain-containing 
adaptor proteins that interact with the TIR domains of 
TLRs. Four TIR adaptor proteins MyD88  [46] , MyD88-adpater 
like (Mal)/TIRAP  [47,48] , TIR domain containing adaptor 
inducing IFN- β (TRIF)  [42,49] and TRIF-related adapter 
molecule (TRAM)  [50-52] integrate TLR activation with 
downstream signalling. MyD88 transduces signals for all 
TLRs with the exception of TLR3, which utilises TRIF 
instead, whilst TRAM and Mal are involved in TLR3 and 
TLR2/4 signalling, respectively. 
 Following its recruitment MyD88 associates with IL-1 
receptor-associated kinase-4 (IRAK-4) ( Figure 2A ) [53]. 
A series of protein-protein interactions then assemble involving 
IRAK-1, TNF receptor-associated factor 6 (TRAF6), TGF-
 β -activated kinase-1 (TAK1) and TAK1-binding proteins, 
TAB1 and TAB2. Ubiquitin conjugating enzyme (Ubc)13 
and ubiquitin-conjugating enzyme E2 variant 1A (Uev1A), 
next catalyse the synthesis of a polyubiquitin chain on 
TRAF6  [54] triggering activation of TAK1 by phosphorylation. 
Activation of the I κ B kinase (IKK) complex (IKK α , IKK β 
and NF- κ B essential modulator (NEMO)/IKK γ )  [55] , ensues 
culminating in phosphorylation, ubiquitylation and proteosomal 
degradation of I κ B and nuclear translocation of NF κ B. 
 Signalling from TLR3 or TLR4 via TRIF and TRAM can 
also trigger a signalling pathway leading to expression of the 
type I interferons. This pathway involves the non-canonical 
IKKs, TANK-binding kinase 1 (TBK1) and IKK ε /IKKi and 
culminates in activation of the transcription factors IRF 3 
and 7 ( Figure 2B )  [50,56,57] which regulate IFN- β and IFN- α 
expression, respectively. 
 TLRs expressed by immune and epithelial cells in the CF 
lung contribute to the pulmonary immune response by 
regulating the production and secretion of chemokines, 
cytokines and antimicrobial peptides and by enhancing cell 
surface adhesion molecules expression. Surface expression of 
intercellular adhesion molecule 1 (ICAM-1) can be increased 
on airway epithelial cells in response to triacylated lipopeptide, 
LPS, uCpG DNA, dsRNA and Influenza virus A  [58,59] . 
Multiple pro-inflammatory cytokines can be regulated by 
TLR activation in these cells. TLR2, TLR4 and TLR9 agonists 
upregulate IL-8, TNF- α and IL-6 amongst others  [58,60-62] . 
IL-8 is a potent neutrophil chemoattractant and a key factor 
regulating the neutrophil-dominated airway inflammation 
characteristic of CF. The expression of other chemokines by 
airway epithelial cells however is also regulated by TLR 
agonists that activate TLRs 2-5. Macrophage inflammatory 
protein 3 (MIP-3) expression, for example, is increased in 
response to zymosan, dsRNA, LPS and flagellin  [63] . 
 The human  β -defensins (HBD) are antimicrobial peptides 
produced by epithelial cells. TLR2 activation by bacterial 
lipoprotein enhances HBD2 expression in tracheobronchial 
epithelium  [64] whilst lipoteichoic acid and peptidoglycan are 
also known to induce TLR2-mediated increases in HBD2 
expression in a variety of airway epithelial cells  [61,65] . TLR4 
agonists, including neutrophil elastase, similarly regulate 
HBD2 expression in both immortalized and primary airway 
epithelial cells  [66] . 
 In addition to microbial agonists, a number of host-derived 
factors with TLR-activation properties have been described. 
Endogenous agonists with activity against TLR2 or TLR4 
include neutrophil elastase, hyaluronan, heat-shock proteins, 
oxidants and fibronectin amongst others  [17,18,67-72] . Stimulation 
of TLRs by these danger-associated molecular patterns 
(DAMPs) points to the existence of mechanisms whereby TLRs 
can recognise host molecular patterns that represent a danger 
signal due to chronic inflammation  [73] . 
TLR1/2 TLR2/6 TLR3 TLR4 mTLR7/
hTLR8
TLR9
uCpGssRNAdsRNA LPS
TLR10
?Triacylated
lipopeptide
Diacylated
lipopeptide
TLR5
Flagellin
 Figure 1 . Microbial Toll like receptor (TLR) agonists. 
dsRNA: Double-stranded RNA; hTLR: Human TLR; LPS: Lipopolysaccharide; mTLR: Murine TLR; ssRNA: Single-stranded RNA; uCpG: Unmethylated CpG dinucleotide motifs. 
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 5.  TLR agonists in the CF lung 
 The CF lung represents a milieu that is potentially rich in a 
variety of microbial ( Figure 1 ) and endogenous TLR agonists. 
It is widely accepted that there are higher than normal levels 
of neutrophil elastase in CF bronchoalveolar lavage fluid whilst 
the presence of both bacterial and yeast-derived factors has 
also been demonstrated  [74] . For example  Pseudomonas DNA 
has been detected in CF sputum and bronchoalveolar lavage 
fluid  [58,75] flagellin expressed by planktonic  Pseudomonas 
may act as a TLR5 agonist in early colonisation and LPS is 
also likely to be present at high levels in the CF lung. TLR2 
agonists such as microbial lipopeptides or lipoteichoic acids 
(LTA) derived from  Pseudomonas and/or  Staphylococcus species 
or fungal-derived factors are other potential candidates. Viruses 
express agonists for TLRs 3, 7 and 8, and viral infections in 
CF have the potential to modulate TLR activity. 
 5.1  The role of viral infection in CF 
 Increasing interest is focusing on the role of viral infections 
in CF in predisposing to bacterial superfection and as 
independent pulmonary pathogens. Up to 40% of pulmonary 
exacerbations are attributed to viruses in individuals with 
CF  [76-78] and are associated with a persistent decrease in lung 
function  [76,78-80] , prolonged hospital admission and increased 
likelihood of earlier acquisition of  Pseudomonas aeruginosa 
colonization  [80,81] . A distinction between upper and lower 
respiratory tract viral infections exists and in CF, increased 
incidences of lower respiratory tract viral infections are 
associated with poorer outcomes  [79] . 
 Viral infection can increase expression of IL-8 thus 
exaggerating the inflammatory cascade  [82] . The co-existence 
of bacterial pathogens can also further predispose to epithelial 
cell damage as part of the inflammatory process, with resultant 
increased transepithelial permeability  [83] . Influenza A infection 
has been associated with neutrophil infiltration  [84] and both 
influenza and adenovirus have cytotoxic effects on airway 
epithelial cells  [85] .  In vitro studies suggest that viruses 
promote increased bacterial adherence to the airways  [86,87] . 
On a molecular level it would appear that viral infection 
interferes with TLR responses. In response to rhinovirus 
human alveolar macrophages showed an impairment of 
IRAK4
IRAK1
TRAF6
IKKα, β, γ
NF-κB
TLR2 or TLR4
Proinflammatory
cytokines
TLR1-2, 4–9
MyD88 MAL
IKKε, TBK1
IRF3/7NF-κB
TLR4
Proinflammatory
cytokines
IFNβ/α
TLR3
TRAM TRIF
Ubc13,
Uev1A TAK1/TAB1/TAB2
A. B.
 Figure 2 . Toll like receptor (TLR) signalling cascades leading to NF- k B or interferon regulatory factor IRF activation. 
A. Following triggering of TLRs 1, 2 and 4-9 the Toll/IL-1R (TIR) domains of TLRs and myeloid differentiation factor 88 (MyD88) interact. 
The signal is transduced via interleukin-1 receptor associated kinase (IRAK)-4, IRAK-1 and TNF receptor-associated factor 6 (TRAF-6). 
Next TRAF6 is ubiquitinated by the E2 ligases ubiquitin conjugating enzyme 13 (Ubc13) and ubiquitin-conjugating enzyme E2 variant 1A 
(Uev1A). This activates transforming growth factor- β -activated kinase-1 (TAK1), which associates with TAK1-binding protein (TAB)1/TAB2 
leading to phosphorylation and activation of the I κ B kinase (IKK) complex, culminating in activation NF κ B which can then translocate to 
the nucleus to regulate gene expression. TLR2 or TLR4 can also activate the IKK complex indirectly via MyD88 adaptor-like (Mal)/MyD88. 
 B. TLR3 and TLR4 activate IKK ε and TBK1 via TIR domain-containing adaptor inducing interferon- β (TRIF)/TRIF-related adaptor molecule 
(TRAM) leading to interferon regulatory factor (IRF)3 and IRF7 activation and production of interferon- β and - α TLR3 can also activate the 
IKK complex via TRIF, leading to classical NF- κ B activation.
TBK1: TANK-binding kinase 1. 
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cytokine responses to bacterial LPS and LTA  [88] thus a 
more thorough investigation of the dynamics of innate 
immunity in CF in the context of both bacterial and viral 
infection is warranted. 
 Prevention and therapeutic strategies for viral infection 
have proven controversial. A Cochrane Review from 2000 
showed no increased protection with influenza vaccine in 
individuals with CF  [89] ; conversely a recent trial has shown 
this may not be the case  [90] . Despite this the vaccine has 
been shown to be safe and is currently recommended for 
individuals with CF. Palivizumab a monoclonal antibody to 
RSV, has been developed for passive immunoprophylaxis 
and has shown some promise. However, there is currently 
no RSV vaccine. 
 The focus of research has recently swung towards antiviral 
therapy to limit the inflammatory response, with limited 
results to date. Ribavirin, a nucleotide analogue, is licensed 
for RSV infection but not in CF, and results have been variable. 
The neuraminidase inhibitors oseltamivir and zanamavir, if 
used early, may be effective for the treatment and prophylaxis 
of influenza infection, and are safe to use. The adamantanes, 
amantadine and rimantadine, are not generally used, and 
resistance rates with these for influenza A of up to 92% 
have been reported  [91,92] . 
 Developing newer strategies for therapy necessitates 
evaluation of more defined viral signalling pathways, and 
should possibly focus on TLR involvement. Viruses detectable 
in CF secretions during exacerbations act mainly through 
TLR3 (influenza A, influenza B, rhinovirus). Signalling 
pathways for parainfluenza virus via TLRs are undetermined 
whereas RSV has been shown to act through TLR4  [14] . 
 6.  Targeting TLRs in CF 
 There are a variety of potential strategies available to interfere 
with TLR function in the CF lung. These include traditional 
approaches such as the use of inhibitory peptides, pharma-
cological methods to promote the expression of endogenous 
anti-TLR molecules or administration of purified versions of 
theses molecules. Exploring the therapeutic properties of 
naturally-occurring TLR antagonists is an area that is also 
likely to have merit. 
 6.1  Endogenous inhibitors 
 Like the autocrine mechanisms that exist to control regulation 
of TNF and IL-1 signalling, a number of endogenous TLR 
inhibitors have been identified that can negatively regulate 
TLR signalling processes. The factors that we will consider 
here are A20, toll interacting protein (Tollip), single 
immunoglobulin IL-1-related receptor (SIGIRR), MyD88s, 
IRAK-M, suppressors of cytokine synthesis (SOCS), sterile 
 α and HEAT-Armadillo motifs protein (SARM), Src 
homolog protein tyrosing phosphatase 1 (Shp-1), protein 
tyrosine phosphatase, non-receptor type 1 (PTP1B), mucin 1 
(MUC1) and peroxisome proliferator activated receptor 
gamma (PPARgamma) ( Table 1 ). This diverse range of 
molecules includes transmembrane proteins and nuclear 
receptors, ubiquitin-modifying and adaptor proteins, kinases 
and phosphatases. Although each of these proteins can 
function to control TLR signalling, their mode of action 
differs; nonetheless, they can commonly be grouped as 
TLR inhibitors. 
 A20 is a ubiquitin-modifying enzyme and zinc-finger 
protein that was first reported to regulate TLR4 signalling  [93,94] . 
It is now known that A20 can suppress both TLR2- and 
TLR4-induced IL-8 expression in airway epithelial cells and 
can be upregulated by measles P virus protein  [95] . Tollip is 
an inhibitor of both IL-1 and LPS signalling  [96] . Inhibition 
by Tollip is mediated through its ability to block the activity 
of IRAK after TLR activation  [97] . Like Tollip, the TIR family 
member TIR8, also known as SIGIRR, is a negative regulator 
of IL-1 and TLR signalling  [98] . An alternatively spliced 
form of MyD88 exists, termed MyD88s. This variant is unable 
to recruit IRAK-4 and thus transcriptionally controls negative 
regulation of innate immune responses to MyD88-dependent 
TLRs  [99] IRAK-M is a novel member of the IRAK 
family  [100] and a negative regulator of TLR signalling  [101] . 
It has an important role in endotoxin tolerance and its 
expression is restricted to monocytes and macrophages. The 
SOCS proteins are induced by stimulation of TLRs and 
both SOCS1 and 3 have been shown to have the ability to 
suppress TLR signalling. Rothlin  et al.  [102] uncovered the 
complex negative feedback mechanism limiting TLR signalling 
involving the Tyro3/Axl/Mer (TAM) family of receptor 
tyrosine kinases, which induce expression of the inhibitory 
proteins SOCS1 and SOCS3. 
 MyD88, Mal, TRIF and TRAM are the four TIR adaptors 
associated with TLR-activation functions. The fifth known 
TIR adaptor, SARM, acts as a negative regulator of 
TRIF-dependent TLR signalling and thus can impair TLR3 
and TLR4 responses  [103] . Recently SHP-1  [104] and PTP1B  [105] 
have been identified as phosphatases that can negatively 
regulate TLR-mediated production of pro-inflammatory 
cytokines by inhibiting activation of the transcription factors 
NF- κ B and MAPK (and IRFs for PTP1B). Interestingly, 
SHP-1 concomitantly increases the production of type I 
interferon mediated by TLRs by directly binding to and 
inhibiting activation of IRAK1. Thus, SHP-1 appears to 
have an important role in skewing the balance between 
expression of pro-inflammatory cytokines and type I interferons 
in the innate immune response  [104] . 
 MUC1 is a transmembrane glycoprotein expressed by 
airway and other epithelial cells. Recently, it has been shown 
to have an anti-inflammatory role particularly with respect 
to  Pseudomonas aeruginosa or its flagellin but also against 
TLR2, 3, 4, 7 and 9 agonists  [106,107] 15deoxy-prostaglandin-J2 
and troglitazone are natural and synthetic PPARgamma 
agonists. Their activation of PPAR-gamma can result in 
reduced stimulation of DCs via the ligands for TLR 2, 3, 4 
and 7  [108] . 
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 6.2  Microbial TLR antagonists 
 In addition to naturally-occurring endogenous TLR inhibitors, 
there exist in nature a number of microbial TLR antagonists 
that may have therapeutic potential for CF ( Table 2 ). To 
date a selection of such microbial proteins have been 
discovered and partially characterised. These include the 
viral proteins A46R, A52R and N1L from  Vaccinia virus 
and RSV G/soluble G protein  [109-112] and the TIR domain-
containing-proteins typhimurium large plasmid A (TlpA) from 
 Salmonella ,  Brucella TIR-containing protein 1 (Btp1)/TIR 
domain containing-protein (Tcp)B from  Brucella spp. and 
TcpC from  Escherichia coli  [113-115] . 
 A46R and A52R share amino acid sequence similarity 
with the mammalian TIR domain and can interfere specifically 
with IL-1 signal transduction  [109] . Ectopic expression of 
A46R can inhibit intracellular signalling by a range of 
TLRs. It targets all four host TIR adaptors MyD88, Mal, 
TRIF and TRAM, and interferes with downstream activa-
tion of NF κ B and MAPKs. A46R also disrupts TRIF-induced 
IRF3 activation and induction of regulated upon activation, 
normally T-expressed, and presumably secreted (RANTES)  [110] . 
A46R is functionally distinct from the other described 
 Vaccinia virus TLR inhibitor, A52R which can potently 
block both IL-1- and TLR4-mediated NF- κ B activation. 
A52R mimics the dominant-negative effect of a truncated 
version of MyD88 on IL-1, TLR4 and IL-18 signalling but 
has no effect on MyD88-independent signalling pathways. 
 Table 1 . Endogenous Toll like receptor (TLR) inhibitors. 
 Protein  Signalling target  Ref. 
A20 TLR2, TLR4  [21,93-95] 
Tollip TLR4 (and IL-1R) at IRAK1  [96,97] 
SIGIRR TLR4 (and IL-1R)  [98] 
MyD88s TLR4 (and IL-1R) Myd88-dependent 
signalling
 [99] 
IRAK-M TLR2, TLR4  [100,101] 
SOCS1/3 TLRs  [102] 
SARM TLR3, TLR4, TRIF-dependent signalling  [103] 
Shp-1 TLR3, TLR4 at IRAK1  [104] 
PTP1B TLRs, MyD88- and TRIF-dependent 
signalling
 [105] 
MUC1 TLR2, TLR3, TLR4, TLR5, TLR7, TLR9  [106,107] 
PPAR γ TLR2, TLR3, TLR4, TLR7  [108] 
 IRAK: Interleukin-1 receptor associated kinase; MyD88: Myeloid differentiation 
factor 88; MUC1: Mucin 1; PPAR γ : Peroxisome proliferator activated receptor 
gamma; PTP1B: Protein tyrosine phosphatase; non-receptor type 1; 
SARM: Sterile  α and HEAT-Armadillo motifs; Shp-1: Src homolog protein 
tyrosing phosphatase 1; SIGIRR: Single immunoglobulin IL-1-related receptor; 
SOCS: Suppressors of cytokine synthesis; Tollip: Toll interacting protein; 
TRIF: TIR domain-containing adaptor inducing interferon- β . 
Together A46R and A52R are used by  Vaccinia virus to 
suppress TIR domain-dependent intracellular signalling. Of 
particular interest here is the demonstration that either 
A46R or A52R, like dominant negative versions of MyD88 
and Mal can interfere with the intracellular mechanisms by 
which neutrophil elastase upregulates inflammatory gene 
expression in both primary and transformed bronchial 
epithelial cells  [60] . 
 Bioinformatics has identified a third  Vaccinia virus protein, 
N1L, which shares significant similarity with A52R  [111] . 
N1L protein strongly affects  Vaccinia virulence  in vivo by 
suppressing NF- κ B and IRF3 activation following engage-
ment TLRs. N1L also disrupts signalling to NF- κ B by the 
TNF superfamily of receptors by targeting the IKK complex 
for inhibition. 
RSV infection of monocyte-derived dendritic cells (mDCs) 
leads to activation of the IFN-inducing pathway leading to 
type I IFN induction. Having shown that RSV initial attach-
ment to cells can block polyI:C-mediated IFN-beta induction 
Shingai  et al.  [112] further demonstrated that polyI:C- or 
LPS-mediated IFN-beta production were inhibited by RSV 
G or soluble G (sG) proteins. These anti-TLR3/4 effects 
were mediated via the TRIF pathway and suppressed the 
production of IFN-beta. The exact molecular mechanism by 
which this inhibition occurs remains to be determined.
 Like viruses, pathogenic bacteria have evolved sophisticated 
molecular strategies to subvert host defenses. Btp1 is a 250 
aa protein expressed by  Brucella abortus that contains a 
C-terminal 130-amino acid domain with significant sequence 
similarity to the TIR domains of TLR2, TLR4, SIGIRR and 
MyD88. This similarity exists both in box 1, the signature 
sequence of the TLR family, and in box 2 which is important 
for signalling  [114] . Btp1 shares homology with TlpA, a 
 Salmonella effector that interferes with TLR signalling 
 in vitro  [113] . Cirl  et al. have also identified a mechanism by 
which virulent bacteria can interfere directly with TLR function 
by secreting proteins that act as inhibitory homologs of the 
mammalian TIR domain  [115] . In addition to the TIR domain 
containing-protein (Tcp) TcpB from  B.  melitensis this group 
also identified a gene encoding a Tcp in  Escherichia coli 
CFT073 (TcpC).  In silico analysis predicts significant tertiary 
structure homology between these proteins and the TIR 
domain of human TLR1. Tcps can directly bind to MyD88, 
impede TLR signalling and suppress innate immunity. 
 6.3  Inhibitory peptides 
 Peptide mimetics that can inhibit agonist binding or signal 
transduction are appealing therapeutic agents for CF. In 
addition to their well-defined specificity, peptides can be 
engineered to gain access to intracellular compartments and 
thus directly interfere with signalling pathways. As a class, 
these low-molecular-weight compounds have significant 
anti-inflammatory potential. To date just a few peptide-blocking 
studies targeting TLRs have been published. Bartfai  et al.  [116] 
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
 Greene, Branagan & McElvaney 
 Expert Opin. Ther. Targets (2008) 12(12) 7
designed and synthesized a low molecular weight MyD88 
mimic, hydrocinnamoyl- L -valyl pyrrolidine, modeled on a 
tripeptide sequence of the BB-loop [(F/Y)-(V/L/I)-(P/G)] of 
the TIR domain. Examination of its pharmacological effects 
focussed on its ability to inhibit IL-1- rather than TLR-mediated 
events but did indicate a concentration-dependent inhibitory 
capacity against IL-1-induced phospho-rylation of p38 MAPK 
in murine lymphocytes.  In vivo , this cell-penetrating TIR 
domain mimic also significantly attenuated IL-1-induced 
fever. Davies  et al.  [117] also tested TIR mimetics based on 
MyD88, whilst Toshchackov and Vogel  [118] performed a 
comprehensive study using a set of blocking peptides comprised 
of the 14 aa corresponding to the sequences of the BB loops of 
MyD88, Mal, TRIF and TRAM linked to the cell-penetrating 
segment of the  Antennapedia homeodomain. TLR4-mediated 
changes in gene expression, as well as MAPK and transcription 
factor activation associated with both MyD88-dependent and 
-independent signalling pathways, were disrupted. All four 
peptides success-fully disrupted TLR4-mediated responses whilst 
TLR2 responses were less well inhibited with the exception 
of a modest effect of the MyD88 peptide on triacylated 
lipopeptide-induced IL-1 β mRNA. The data suggest that the 
adapter BB loops of different MyD88 adaptor proteins may 
serve distinct roles in TLR4 and TLR2 signalosome assembly. 
This specificity is likely to determine the effectiveness of 
developing TIR-based peptides as anti-inflammatory drugs. 
 6.4  Anti-TLR properties of pulmonary antiprotease 
 Although classically regarded as antiproteases, secretory 
leukoprotease inhibitor (SLPI), elafin, and alpha-1 antitrypsin 
(A1AT) also function as antimicrobial agents. Each has 
potential anti-TLR activity. 
 Table 2 . Microbial Toll like receptor (TLR) antagonists. 
 Protein  Organism  Target  Ref. 
A46R Vaccinia virus TLR3, TLR4 at TRIF, 
TRAM, MyD88, Mal
 [109,110] 
A52R Vaccinia virus TLR4 (IL-1, IL-18)  [109,110] 
N1L Vaccinia virus TLR2, TLR3, TLR4 at 
IKK complex
 [111] 
RSV sG RSV TLR3, TLR4  [112] 
TlpA  Salmonella eneterica 
serovar Enteritidis
TLR4 (IL-1) at 
MyD88
 [113] 
Btp1  Brucella abortus TLR2  [114] 
TcpP  Brucella melitensis TLRs at MyD88  [115] 
TcpC  Escherichia coli TLRs at MyD88  [115] 
 Btp1:  Brucella TIR-containing protein 1; IKK: I κ B kinase; Mal: MyD88 adaptor-like; 
MyD88: Myeloid differentiation factor 88; RSV: Respiratory syncytial virus; 
TlpA: Typhimurium large plasmid A; Tcp: TIR domain containing-protein; 
TRAM: TRIF-related adaptor molecule; TRIF: TIR domain-containing adaptor 
inducing interferon- β . 
 6.4.1  Slpi 
 SLPI is an 11.7 kDa protein, secreted by airway epithelial 
cells  [119] . Along with A1AT, it comprises the body’s major 
antineutrophil elastase defence  [120] . As an antiprotease, it 
has been shown to protect tissue locally by inhibiting other 
proteases such as trypsin, chymotrypsin, chymase, tryptase and 
cathepsin G  [121] . In addition to its antiprotease actions 
SLPI has been shown to have anti-infective and anti-
inflammatory properties  [122] . It displays antimicrobial action 
against  Pseudomonas aeruginosa ,  Staphylococcus aureus and 
 Candida albicans  [123,124] . Other studies have also demonstrated 
its anti HIV properties  [125] . 
 With respect to targeting TLRs, SLPI has been shown 
to inhibit TLR- induced cytokine expression, impairing 
TLR2- and TLR4-mediated responses in monocytic cells. 
In the setting of CF, bacterial colonization and persistent 
infection, particularly with  Pseudomonas aeruginosa is one of 
the main determinants of morbidity and mortality in patients, 
thus inhibition of TLR2- and TLR4-mediated responses by 
SLPI underlines its therapeutic potential in this area  [126] . 
Interestingly LPS is known to upregulate SLPI production 
in macrophages suggesting the existence of a novel endogenous 
negative feedback loop  [127] . 
 The mechanisms by which SLPI interferes with LPS 
effects are dependent on its antiprotease activity and involve 
impairing degradation of I κ B α without affecting phospho-
rylation or ubiquitination  [128] and by binding directly to 
p65 NF κ B binding sites in a site-specific manner  [129] . 
 SLPI as an anti fungal is also of potential importance 
in the CF population.  Aspergillus colonization is associated 
with accelerated lung function decline and poorer overall 
outcomes. Recombinant SLPI (rSLPI) has been shown 
to dose-dependently kill hydrated but not airborne 
conidia  [130] . The same group found a partial inhibition 
of fungal protease activity ( A. fumigatus virulence factor) 
by rSLPI, and this also inhibited the induction of the 
pro-inflammatory cytokine response in airway epithelial 
cell lines  [131] . 
 Excessive mucus production as a result of an exacerbation 
of CF is a huge symptomatic problem for the patient, 
particularly when difficult to expectorate, and leads to 
increased patient anxiety, as well as detrimental effects on lung 
function and worsening respiratory failure. SLPI’s potential 
as an antimucin agent in CF has also been highlighted  [132] 
in a study that demonstrated its inhibitory capacity against 
TLR2, TLR4 and TLR9 agonist-induced MUC2 and 5AC 
expression via a mechanism primarily dependent on the 
inhibition of TGF- α release. SLPI may therefore have a 
potential role as an antimucin agent in CF. 
 6.4.2  Elafi n 
 Elafin is a 6 kDa serine antiprotease expressed in mucosal 
surfaces  [133] . Pre-elafin, also known as trappin 2, is its 
precursor which undergoes proteolytic cleavage to release 
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mature elafin  [134] . There is increasing interest in this anti-
protease as an immunomodulatory molecule. Cytokine-mediated 
increases in elafin production by epithelial cells are greater 
than the increase in SLPI production  [135] , and it has been 
suggested that elafin is of greater significance during an 
inflammatory challenge to the lungs. Antimicrobial properties 
have been described for elafin against  Pseudomonas aeruginosa 
and  Staphylococcus aureus  [123] . 
 As an anti inflammatory agent elafin can inhibit LPS-induced 
production of monocyte chemotactic protein 1 (MCP-1) 
in monocytes. This effect is mediated via impairment of 
both AP-1 and NF- κ B activation, via an effect on the 
ubiquitin-proteasome pathway  [136] . Elafin also has anti-
fungal properties  [137] . Thus, like SLPI, elafin may hold 
therapeutic promise in the treatment of inflammation and 
infection in CF. 
 6.4.3  A1at 
 A1AT is the body’s most abundant serine antiprotease. Increasing 
evidence exists to suggest that A1AT possesses properties 
other than its antiprotease function including both anti-
inflammatory and immunododulatory effects. For example 
native, polymerised or oxidised A1AT can inhibit LPS-
stimulated synthesis of TNF- α and IL-1 β whilst enhancing 
the release of the anti-inflammatory cytokine IL-10  [138] . 
Whether A1AT has direct anti-TLR4 activity remains to
be shown, however, C-36 peptide, a degradation product of 
A1AT, also has potential LPS-modulatory activity against 
human monocytes  [139] . 
 7.  Delivery of therapeutics to the CF lung 
 A major hurdle in targeting therapeutics to treat the pulmonary 
inflammatory manifestations of CF is the effective delivery 
of an agent to the lung. The presence of biofilm, excessive 
mucus and parenchymal damage in the CF lung can negatively 
affect drug distribution and bioavailability. Whilst aerosol 
delivery ensures direct administration to the site of action and 
less systemic toxicity, its drawbacks include problems in 
sampling of epithelial lining fluid to quantify anti-inflammatory 
effects and determine pharmacokinetics. An ideal aerosolised 
therapeutic agent for CF should be sterile, nonpyrogenic, 
chemically stable and have a particle size ranging from 1 to 
5 µm for reproducible drug delivery to the airways  [140,141] . 
The drug should have a wide margin of dosage safety to 
allow for the varying conditions in the lungs of CF patients 
and should be easily nebulised. 
 8.  Current therapeutics and their effect on TLRs 
 Continuous cycles of infection lead to increased morbidity 
and mortality in the setting of CF. Prompt antibiotic therapy 
based on appropriate sensitivities is associated with reduced 
decline in lung function and improved patient outcomes. 
Symptomatically, inhaled/nebulised broncho-dilator therapy 
provides relief from breathlessness, and mucolytic therapy 
can be very useful in enabling patients to expectorate sputum. 
There is increasing focus on therapy targeting the underlying 
pathogenesis, and in particular underlying inflammation. 
 8.1  Anti-infl ammatory therapies 
 The underlying inflammatory state is central to the disease 
process, and many therapies have been initiated in an effort 
to counter this, including NSAID’s, steroids, and, more 
recently azithromycin. Initial studies looking at diffuse 
pan bronchiolitis in Japan showed improvement with 
macrolide therapy  [142] . Studies in CF have shown similar 
improvements, with improved forced expiratory volume in one 
second (FEV1), reduced number of hospital admissions, 
increased weight, and improved quality of life  [143-145] . 
Azithromycin is a macrolide antibiotic, and in addition 
to its antibacterial properties which may include effects 
on biofilm formation, may have anti inflammatory  [146] 
and immunomodulatory effects. 
 For example, azithromycin has been shown to reduce 
TNF- α levels in CF airway epithelial cells  [147] and to suppress 
activation of NF- κ B and pro inflammatory cytokine expression 
in tracheal aspirate cells from premature infants  [148] . Some 
evidence exists for TLR4- and TLR5-specific properties of 
azithromycin. An experimental model has shown that 
azithromycin attenuates the effects of LPS administration in 
mice  [149] . Azithromycin has been shown to reduce expression of 
 Pseudomonas aeruginosa flagellin  [150,151] . A more recent model, 
with  Salmonella typhimurium , has shown that azithromycin 
inhibits the formation of flagellar filaments without suppressing 
flagellin synthesis  [152] . 
 Glucocorticoids are well documented as anti inflammatory 
agents but chronic use is associated with long-term sequelae 
including osteoporosis, peptic ulcer disease and cataracts. 
Their mechanism of action is associated with upregulation 
of TLRs although they can impair the differentiation and 
antigen presenting ability of dendritic cells  [153] . 
 8.2  Mucolytic therapies 
 Nebulised hypertonic saline has been shown to be useful for 
sputum induction in the setting of CF, and short-term 
studies have shown improved pulmonary function following 
treatment  [154,155] . Recently it has been shown in a mouse 
model post thermal injury that hypertonic saline enhances host 
defense to bacterial challenge by augmenting TLRs  [156] . 
Nebulised hypertonic saline, although a different mode of 
delivery and for a different purpose, may in fact work in a 
similar way. 
 Dornase alfa, a DNAse, has been shown to reduce 
viscosity of sputum, allowing easier expectoration. Improve-
ments in lung function have also been documented  [157,158] . 
Viscosity is decrease d by enzymatic degradation of host and 
bacterial DNA, with the added advantage that TLR9-
mediated signalling in response to uCpG DNA is likely to 
be abrogated also. 
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 8.3  Delivery of agents to the CF lung 
 The mucus lining the airways of the CF lungs is a complex 
biological environment posing significant barriers to efficient 
therapeutic drug delivery. CF mucus, which acts as the primary 
extracellular barrier in the CF lung contains mucin fibres that 
form a dense matrix intertwined with other macromolecules 
such as actin and DNA that decrease its permeability. The 
viscoelasticity of CF sputum greatly reduces the diffusion rates 
of colloidal particles, limiting the effectiveness of drug delivery 
to underlying lung cells. According to Dawson  et al.  [159] , 
nanoparticles dispersed in CF sputum are transported primarily 
through lower viscosity pores within a highly elastic matrix. 
Neutral particles with a diameter of less than 200 nm undergo 
more rapid transport in CF sputum than charged or 
larger particles. Whilst DNase can reduce the macro-
viscoelastic properties of CF sputum by up to 50% by 
hydrolyzing chromosomal DNA released from dead neutro-
phils, surprisingly, it does not significantly alter the 
average particle diffusion rate. This is most probably due an 
increased microviscosity  [160] . 
 Polyethylene glycol (PEG)ylated poly- L -lysine nano-
particles have been used to efficiently transfect lung epithe-
lium following intrapulmonary administration  [161] . This 
technology could assist any inhaled therapeutic in penetrating 
the airways. 
 9.  Concluding remarks 
 As a major portal of entry for bacteria and microbes, the 
lung represents a key component of the innate immune 
system. Airborne pathogens encounter a number of effective 
defense mechanisms designed to rapidly counteract potential 
damage, inhibit colonization and protect against invasion by 
pathogens. The existence of TLRs equips the lung with an 
exquisitely designed mechanism for controlling microbial 
infection. Unfortunately CF is a disease in which the lung is 
so badly affected that innate immunity and TLR activity are 
dysfunctional. Thus, modulation of TLR function has obvious 
important implications. Enhancing TLR responses using targeted 
approaches directed at TLR3 could accelerate antiviral 
responses. Conversely suppression of other TLR responses, 
by the use of appropriate inhibitors could reduce the chronic 
inflammation characteristic of this disease. Thus, new thera-
peutics designed to selectively activate or inhibit TLR function 
specifically and reversibly represent powerful tools for the 
prevention and treatment of the pulmonary inflammatory 
manifestations of CF. 
 10.  Expert opinion 
 TLR-targeted approaches to the management of inflammation 
and infection in CF differ with respect to bacterial and viral 
factors. In chronic bacterial colonization, as seen in CF, the 
problem is partly one of an overexuberant inflammatory 
response, which may need to be dampened down or be made 
more effective in clearing bacteria. With respect to viral 
infection the focus is on enhancing rather than inhibiting type I 
interferon production in an attempt to eliminate the virus as 
soon as possible. Thus, the challenge is to design appropriate 
TLR-directed therapeutics with selective properties. In this 
regard designing drugs that activate or interfere with 
components of the signalling pathways rather than the 
TLRs themselves would appear to be the more targeted 
strategy. Progress in this area will be guided by the emerging 
knowledge regarding the mechanisms by which endogenous 
and microbial antagonists of TLR signalling exert their 
effects at a molecular level. 
 Manipulation of TLR signalling has inherent risks that 
must be carefully considered. Immunosuppression in the 
face of constant bacterial and fungal challenge may allow 
spread of infection and involvement of previously undamaged 
lung tissue. Therefore, until such time as we know the level 
of inflammation required to confine infection we must be 
conservative in our immunosuppressive approaches and any 
new trials must include careful monitoring of sputum organ-
isms, inflammatory mediators, lung function and structural 
changes. Currently we are at a point where we are faced with 
determining how best to identify and minimize adverse events. 
By studying patients with known deficiencies in TLR signalling 
(e.g IRAK-4  [162] ), we may be able to identify pathway-specific 
events that represent hallmarks of adverse suppressive effects. 
The corollary to this exists when attempting to enhance TLR 
function. Immunostimulatory therapies can create an 
undesirable ‘hypercytokine’ milieu. Data from animal studies 
will help to decipher such events. Indeed impairing antiviral 
immunity may actually confer an unexpected benefit as per 
the recent demonstration of an unexpected survival advantage 
in influenza-virus-infected mice deficient in TLR3, despite 
higher viral production in the lungs  [163] . Thus, on balance, 
given that CF airways have aberrantly high cytokine levels 
even in the absence of detectable microbial infection, TLRs 
antagonists would appear to be the way forward. 
 With respect to existing conventional therapies there is 
evidence that many of these approaches directly or indirectly 
affect TLR-mediated responses and that their efficacy is 
mediated by this. We can learn a lot from current conven-
tional therapies. We have seen that many of these, for example 
azithromycin or hypertonic saline exert their effects at least 
partly via TLRs. By understanding in more detail how these 
modulate the activity of TLRs to good effect we can design 
TLR-directed interventions that selectively inhibit the 
inflammatory part of the cascade whilst retaining the anti-
microbial component. As with all therapeutic approaches for 
CF our enthusiasm for success must be tempered with a 
degree of caution. Important considerations for effective 
therapies, for example the use of A1AT augmentation therapy, 
or indeed any antiprotease therapy, designed to treat the 
pulmonary manifestations of CF include effective deposition 
in poorly aerated areas and protection against degradation 
and inactivation by serine and cysteinyl cathespins present 
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in the CF airways. These challenges must remain at the 
forefront of our scientific and clinical thinking. 
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